 |
|
|
|
|
|
|
|
|
|
 |
|
| |
|
 |
BioValve Technologies, Inc. -- speciality drug delivery company
BioValve Technologies, Inc. is a specialty drug delivery company focusing on the development of the optimized delivery of new chemical entities that support the treatment of conditions of the central nervous system. The lead agents in BioValve's portfolio are D1 and D2 selective dopamine agonists for treatment of Parkinson's disease and schizophrenia. BioValve currently has multiple pharmaceutical collaborations in place and is developing several product-device combinations through FDA approval. BioValve is also the parent company of Valeritas, LLC, which was spun out of BioValve to develop the V-goTM, a novel disposable basal-bolus insulin patch for type 2 Diabetics.
www.biovalve.com
|
| |
| ^ back to top |
| |
| |
| Coserics, LLC |
Coserics, LLC -- supportive-care oncology pharmaceuticals
Coserics is a Durham, North Carolina-based biotech company developing treatments for the supportive-care oncology market. The company's lead compound, SNX-1012, is in phase 2 clinical testing for treatment of chemotherapy induced oral mucositis in solid tumor patients.
|
| |
| ^ back to top |
| |
| |
 |
Sopherion Therapeutics, Inc. -- oncology-focused specialty biopharmaceuticals
Sopherion Therapeutics is a biopharmaceutical company focused on developing and marketing anti-cancer therapies for patients suffering with advanced cancer, including metastatic disease. Sopherion's lead product is Myocet®, a liposome-encapsulated doxorubicin-citrate complex. Extensive clinical studies of Myocet® in women with breast cancer have shown that the severe toxicity of doxorubicin to the heart and the cells that line the gastrointestinal tract can be significantly moderated while the efficacy of the drug is maintained. Myocet® has been approved by the European and Canadian regulatory agencies for first line therapy for patients with metastatic breast cancer. Sopherion is currently conducting a pivotal Phase 3 registration study of Myocet® for the first line treatment for patients with metastatic HER2+ breast cancer in combination with Genentech's Herceptin (trastuzumab). Results from the Phase 3 study are expected in 2009.
www.sopherion.com
|
| |
| ^ back to top |
| |
| |
 |
Targanta Therapeutics, Corp. (NASDAQ:TARG) -- developing novel antibioticsbacterials for serious infections
Targanta Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative antibiotics to treat serious infections in the hospital and other institutional settings. The Company Targanta is developing its lead antibiotic, oritavancin, in an intravenous (IV) formulation for the treatment of serious gram-positive bacterial infections, including complicated skin and skin structure infections, or cSSSI, and bacteremia, a blood stream infection. Targanta submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in February 2008 seeking to commercialize IV oritavancin for the treatment of cSSSI. Additionally, Targanta is developing a number of antibacterial agents currently in pre-clinical development including an oral version of oritavancin targeting Clostridium difficile-related conditions. Targanta has exclusive worldwide rights to 's strategy is to develop oritavancin into a leading therapy worldwide for the treatment of serious gram-positive infections, initially for the treatment of cSSSI and subsequently for other indications. The Company has operations in Cambridge, MA, Indianapolis, IN, and Montreal, Québec, Canada. Seaflower was the lead investor in Targanta's first two venture financing rounds, negotiated the acquisition of oritavancin, and recruited the management team.
Targanta raised $57.5 million in an IPO on NASDAQ in October 2007. The Company's common stock trades on the NASDAQ under the symbol: TARG
www.targanta.com
|
| |
| ^ back to top |
| |
| |
 |
Valeritas, Inc. -- novel, convenient insulin delivery solutions for diabetic patients
Valeritas, Inc. is a medical technologies company serving the fast-growing diabetes market with proprietary drug delivery systems. The company's lead product, V-Go™, is an FDA-approved, simple-to-use, disposable insulin delivery device that provides both continuous basal dosing and on-demand mealtime bolus dosing. The V-Go™ is designed to help enhance glycemic control and to improve compliance in type II diabetics.
www.valeritas.com
|
| |
| ^ back to top |
| |
| |
 |
Zelos Therapeutics, Inc. -- PTH therapies for osteoporosis and other diseases
Zelos Therapeutics specializes in the development of innovative treatments for bone disorders and related indications in large, underserved markets. Zelos is advancing a portfolio of product opportunities into late stage clinical trials and pursuing programs linked by the common mechanism of stimulating bone formation to provide therapeutic benefit in the following key indications: osteoporosis; bone marrow/stem cell transplantation; fracture repair; renal bone disease; and multiple myeloma. Zelos's lead compound is ZT-031, a proprietary cyclic 31-amino acid parathyroid hormone (PTH) analog. In a twelve- month Phase 2 study in postmenopausal women with low bone mass, ZT-031 demonstrated its capacity as a powerful bone formation agent, having a rapid onset of effect leading to clinically important increases in bone mineral density (BMD) with low potential for calcium related toxicity. Our target markets include the large market in osteoporosis created by Lilly's Forteo® (teriparatide). Zelos Therapeutics is headquartered in West Conshohocken, Pennsylvania. Seaflower was the lead investor in Zelos's Series A venture capital financing round, incubated the company's initial U.S. headquarters, and recruited the initial management team.
www.zelostherapeutics.com
|
| |
| ^ back to top |
| |
| |
|
|
 |
|
|
|
|
|
|
|
 |
|
|
|
